Castle Biosciences Inc
NASDAQ:CSTL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.4
34.67
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Castle Biosciences Inc
Castle Biosciences Inc
PP&E Net
Castle Biosciences Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Castle Biosciences Inc
NASDAQ:CSTL
|
PP&E Net
$56.3m
|
CAGR 3-Years
85%
|
CAGR 5-Years
99%
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
PP&E Net
$5.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
9%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
PP&E Net
$2.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
|
CVS Health Corp
NYSE:CVS
|
PP&E Net
$29B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
13%
|
|
|
Cigna Corp
NYSE:CI
|
PP&E Net
$3.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
9%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
PP&E Net
$3.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
15%
|
|
Castle Biosciences Inc
Glance View
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
See Also
What is Castle Biosciences Inc's PP&E Net?
PP&E Net
56.3m
USD
Based on the financial report for Sep 30, 2024, Castle Biosciences Inc's PP&E Net amounts to 56.3m USD.
What is Castle Biosciences Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
99%
Over the last year, the PP&E Net growth was 66%. The average annual PP&E Net growth rates for Castle Biosciences Inc have been 85% over the past three years , 99% over the past five years .
You don't have any saved screeners yet
